CALGARY, Alberta--(BUSINESS WIRE)--Tourmaline Oil Corp. (TSX: TOU) ("Tourmaline") and Clean Energy Fuels Corp. (NASDAQ: CLNE) ("Clean Energy") announced today the opening of two new compressed natural ...
Cardiovascular disease can be managed with drugs that take various approaches, but few of them work by reducing inflammation. Novartis is getting an anti-inflammatory drug candidate through its $1.4 ...
– Novartis to acquire Tourmaline Bio (TRML) for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a ...
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as ...
Tourmaline will be focused on advancing TOUR006, its differentiated anti-IL-6 antibody, to treat thyroid eye disease (TED), atherosclerotic cardiovascular disease (ASCVD) and other diseases ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results